A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.

← catalyst calendar

NCT07152119 · readout in 1,311 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

—

Status

Recruiting

Study type

Observational

Enrollment

3,000estimated

Sites

Country

South Korea

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-08-27

actual

When the study began enrolling

Primary completion

2030-03-23

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2030-03-23

estimated

The whole study's end, after follow-up

First posted

2025-09-03

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-18

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Severe Alopecia Areata

Intervention

Drug: Litfulo — also filed as Ritlecitinib tosylate (ATC code: L04AF08)

Primary outcomes

what the primary-completion date above is the date OF

Frequency and proportion of AEs/ADRs

measured 24 weeks (Regular surveillance), 48 weeks (Long-term surveillance)

Frequency and proportion of unexpected AEs/ADRs

measured 24 weeks (Regular surveillance), 48 weeks (Long-term surveillance)

Frequency and proportion of SAEs/SADRs

measured 24 weeks (Regular surveillance), 48 weeks (Long-term surveillance)

Frequency and proportion of AESI

measured 24 weeks (Regular surveillance), 48 weeks (Long-term surveillance)

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed